Scott W Cousins
Overview
Explore the profile of Scott W Cousins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
2466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ehlers J, Hu A, Boyer D, Cousins S, Waheed N, Rosenfeld P, et al.
Ophthalmol Sci
. 2024 Nov;
5(1):100628.
PMID: 39605874
Objective: This study evaluated the safety and efficacy of elamipretide in dry age-related macular degeneration (AMD) with noncentral geographic atrophy (GA). Design: ReCLAIM-2 was a prospective, phase II, randomized, placebo-controlled,...
2.
Lee T, Amason J, Del Risco A, Kim J, Cousins S, Hadziahmetovic M
J Vitreoretin Dis
. 2023 Apr;
6(2):138-146.
PMID: 37008662
Purpose: This work tests the feasibility of remote ophthalmic imaging to identify referable retinal abnormalities and assesses the effectiveness of color fundus photography (CFP) vs optical coherence tomography (OCT) for...
3.
Soifer M, Azar N, Blanco R, Mousa H, Ghalibafan S, Tovar A, et al.
Ocul Surf
. 2022 Dec;
27:77-79.
PMID: 36464234
No abstract available.
4.
Allingham M, Mettu P, Cousins S
Ophthalmol Sci
. 2022 Oct;
2(1):100095.
PMID: 36246187
Purpose: To assess safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with intermediate age-related macular degeneration (AMD) and high-risk drusen (HRD) and to perform...
5.
Mettu P, Allingham M, Cousins S
Ophthalmol Sci
. 2022 Oct;
2(1):100086.
PMID: 36246181
Purpose: Assess the safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with dry age-related macular degeneration (AMD) and noncentral geographic atrophy (NCGA) and to...
6.
Allingham M, Loksztejn A, Cousins S, Mettu P
Adv Exp Med Biol
. 2021 Apr;
1256:143-189.
PMID: 33848001
Increasing evidence over the past two decades points to a pivotal role for immune mechanisms in age-related macular degeneration (AMD) pathobiology. In this chapter, we will explore immunological aspects of...
7.
Zhuang J, Madden D, Cunha P, Badea A, Davis S, Potter G, et al.
Neuroimage Clin
. 2021 Mar;
30:102594.
PMID: 33662707
Age-related macular degeneration (AMD) is a common retina disease associated with cognitive impairment in older adults. The mechanism(s) that account for the link between AMD and cognitive decline remain unclear....
8.
Mettu P, Allingham M, Cousins S
Prog Retin Eye Res
. 2020 Oct;
82:100906.
PMID: 33022379
Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the treatment of neovascular age-related macular degeneration (NVAMD). However, many patients suffer from incomplete response to anti-VEGF therapy (IRT), which is...
9.
Rasti R, Allingham M, Mettu P, Kavusi S, Govind K, Cousins S, et al.
Biomed Opt Express
. 2020 Mar;
11(2):1139-1152.
PMID: 32133239
Anti-vascular endothelial growth factor (VEGF) agents are widely regarded as the first line of therapy for diabetic macular edema (DME) but are not universally effective. An automatic method that can...
10.
Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms
Allingham M, Mettu P, Cousins S
Exp Eye Res
. 2019 Sep;
188:107788.
PMID: 31479654
Diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the two most common retinal vascular diseases and are major causes of vision loss and blindness worldwide. Recent and ongoing development...